ASML

1,189.2

+6.48%↑

SAP

150.62

-0.99%↓

IFX

38.29

+4.76%↑

NOKIA.FI

6.91

+2.67%↑

STMPA.FR

26.97

+3.65%↑

ASML

1,189.2

+6.48%↑

SAP

150.62

-0.99%↓

IFX

38.29

+4.76%↑

NOKIA.FI

6.91

+2.67%↑

STMPA.FR

26.97

+3.65%↑

ASML

1,189.2

+6.48%↑

SAP

150.62

-0.99%↓

IFX

38.29

+4.76%↑

NOKIA.FI

6.91

+2.67%↑

STMPA.FR

26.97

+3.65%↑

ASML

1,189.2

+6.48%↑

SAP

150.62

-0.99%↓

IFX

38.29

+4.76%↑

NOKIA.FI

6.91

+2.67%↑

STMPA.FR

26.97

+3.65%↑

ASML

1,189.2

+6.48%↑

SAP

150.62

-0.99%↓

IFX

38.29

+4.76%↑

NOKIA.FI

6.91

+2.67%↑

STMPA.FR

26.97

+3.65%↑

Search

Societe BIC SA

Uždarymo kaina

SektoriusTechnologijų sektorius

51.8 1.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

50.7

Max

52.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-66M

9.8M

Pardavimai

-64M

1B

P/E

Sektoriaus vid.

12.813

77.27

Dividendų pajamingumas

4.42

Pelno marža

0.963

Darbuotojai

13,000

EBITDA

-190M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+0.39% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.42%

2.29%

Kitas uždarbis

2026-04-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-142M

2.2B

Ankstesnė atidarymo kaina

50.63

Ankstesnė uždarymo kaina

51.8

Naujienos nuotaikos

By Acuity

25%

75%

65 / 376 reitingas Technology

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Societe BIC SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-03-23 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026-03-23 23:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-23 23:59; UTC

Rinkos pokalbiai

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026-03-23 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026-03-23 23:37; UTC

Rinkos pokalbiai

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:23; UTC

Rinkos pokalbiai

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026-03-23 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026-03-23 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026-03-23 22:08; UTC

Rinkos pokalbiai

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026-03-23 21:10; UTC

Svarbiausios naujienos

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026-03-23 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai
Uždarbis
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Societe BIC SA Prognozė

Kainos tikslas

By TipRanks

0.39% į viršų

12 mėnesių prognozė

Vidutinis 52 EUR  0.39%

Aukščiausias 53 EUR

Žemiausias 51 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Societe BIC SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

55.4 / 57.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

65 / 376 reitingas Technologijų sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Societe BIC SA

Société BIC SA manufactures and sells stationery, lighter, shaver, and other products worldwide. It offers ball and coloring felt pens, glitter pens, markers, graphic and coloring pencils, shavers, mechanical pencils, sticky notes, printing products, stationery dyes, leads, white boards, correction tapes; pocket, utility, and decorated lighters; paints, gouache, watercolor, gels, highlighters, and various other products. The company also provides refillable shavers, permanent and temporary tattoo markers, semi permanent tattoo, and smart reusable notebooks, kits, crafting accessories, modeling clay and slime, refills, razor for men and women, and razor cartridges. In addition, it sells batteries and shaving preps; and advertising and promotional products. Further, the company is involved in the provision of delivery services; production of industrial equipment; manufacture and sale of blades; and manufacture and distribution of IT solutions and consumer products, as well as insurance activities. It markets its products primarily under the BIC, BIC Kids, Cello, Lucky, RocketBook, Tipp-Ex, BIC Wite-Out, Tattly, ami, DJEEP, InkBox, BIC Soleil, BIC Evolution, BodyMark, and other brands through a range of channels, including retail mass-market distributors, traditional stores, and office product suppliers, as well as an e-commerce site. The company was founded in 1944 and is headquartered in Clichy, France.
help-icon Live chat